---
title: "Nascent Biotech, Inc. (NBIO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NBIO.US.md"
symbol: "NBIO.US"
name: "Nascent Biotech, Inc."
industry: "Biotechnology"
---

# Nascent Biotech, Inc. (NBIO.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.nascentbiotech.com](https://www.nascentbiotech.com) |

## Company Profile

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.14 | 96/605 | - | - | - |
| PB | -0.54 | 495/605 | - | - | - |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/NBIO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NBIO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NBIO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.